TG Therapeutics (FRA:NKB2) Total Debt per Share : €1.56 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Total Debt per Share?

€1.56 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. TG Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 was €1.56.

TG Therapeutics Total Debt per Share Historical Data

The historical data trend for TG Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Total Debt per Share Chart

TG Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Debt per Share

Get a 7-Day Free Trial

0.25

0.49

0.54

0.67

1.56

TG Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Debt per Share	Get a 7-Day Free Trial															0.67	0.67	0.68	1.47	1.56

TG Therapeutics Total Debt per Share Calculation

TG Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(241.2	+	1.1)	/	155.8
	=	1.55

TG Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(241.2	+	1.1)	/	155.8
	=	1.55

TG Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Total Debt per Share

Comparable Companies

Traded in Other Exchanges

TGTX:USA 0VGI:UK

Address

3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines